Complementary expression patterns of pSTAT5 and pSTAT3 in human ADH.

<p>A. Representative IHC staining for pSTAT5 (top panel) and pSTAT3 (bottom panel) in consecutive ADH lesions. B-C. Inverse correlation between percentage of pSTAT5+ and pSTAT3+ cells in ADH (B) or normal TDLU (C). Each dot represents an individual ADH lesion (B) or TDLU (C).</p

Cell proliferation rates in human ADH and their relationships with pSTAT5 and pSTAT3.

<p>A. Quantification of Ki67 staining in normal TDLU, ADH, and UDH. B-C. No association between percentage of pSTAT5+ (B) and Ki67+ cells or between pSTAT3+ (C) and Ki67+ cells in ADH. Each dot represents an individual ADH lesion.</p

Cell apoptosis rates in human ADH and their relationships with pSTAT5 and pSTAT3.

<p><b>A</b>. Quantification of TUNEL assay in normal ducts, ADH, and UDH. B-C. B-C. No association between percentages of pSTAT5+ (B) and TUNEL+ cells or between pSTAT3+ (C) and TUNEL+ cells in ADH. Each dot represents an individual ADH lesion.</p

pSTAT5 and pSTAT3 status in human ADH.

<p>A. H&E staining (top panel), pSTAT5 (mid panel), and pSTAT3 IHC staining (bottom panel) of normal TDLU, ADH, UDH, and ADH-adjacent ducts. B. Quantification of pSTAT5 staining in normal TDLU, pure ADH, tumor-adjacent ADH (TA-ADH), and UDH, and pairwise comparisons shown by horizontal lines. C. Paired comparison for percentage of pSTAT5 positive cells in ADH and corresponding ADH-adjacent normal ducts. D. Quantification of pSTAT3 staining in normal TDLU, pure ADH, tumor-adjacent ADH (TA-ADH), and UDH, and pairwise comparisons shown by horizontal lines. E. Paired comparison for percentage of pSTAT3-positive cells in ADH and corresponding ADH-adjacent normal ducts.</p

Boletín de Segovia: Número 145 - 1872 noviembre 20

Copia digital. Madrid : Ministerio de Cultura. Subdirección General de Coordinación Bibliotecaria, 200

Additional file 2: Figure S1. of Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer

BGJ398 treatment in Wnt1/iR1 tumors results in rapid apoptosis of luminal cells and downregulation of protein translation pathways. A. Immunofluorescence double staining of K5 (red) and K8 (green) in tumors from control or treatment groups (48 hours after BGJ398 treatment). Yellow arrows indicate the areas of apoptosis. Nuclear staining is shown in blue (DAPI). B. Immunoblot analysis of p-mTOR and p-4E BP1 in Wnt1/iR1 tumors with BGJ398 treatment. Beta-actin was used as a loading control. C. Protein expression levels in Wnt1/iR1 tumors 6 and 24 hours after treated with BGJ398 as compared to control determined through RPPA analysis. (TIF 18070 kb

Additional file 1: Table S1. of Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer

List of antibodies and reagents. (PDF 33 kb